Axsome Shares Rise 19% in a Month: What's Driving the Rally?

Axsome Therapeutics’ (AXSM) shares have rallied 19.4% in the past month against the industry’s decrease of 0.2%, driven by investor enthusiasm about the company’s encouraging preliminary sales numbers for the fourth quarter and full year 2024.Axsome’s commercial portfolio includes Auvelity (AXS-05) which was launched in the United States in 2022 to treat major depressive disorder. It was the company’s first approved drug.The company is conducting several label expansion studies on Auvelity targeting other c ...